aptaTargets - Biopharmaceutical company focused on the development of all types of therapeutic applications based on aptamer technology .
Employees: 11-50
Total raised: $3.01M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 05.08.2021 | Caixa Capi... | caixacapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.05.2017 | - | $3.01M | - |
Mentions in press and media 5
| Date | Title | Description |
| 04.11.2020 | EIT Health startups see strong Q3 with €72.7 million funding raised | EIT Health-supported startups have reported a successful quarter three in terms of fundraising, with €72.7 million secured. The 19 startups hail from 10 European countries and will use the funds to further develop their solutions addressin... |
| 14.10.2020 | aptaTargets closes a second financing round of 5 million euros | The company aptaTargets has closed the second round of financing, with the participation of Inveready and the CDTI, through its INNVIERTE program, which will allow it to mobilize up to 5 million euros between 2020 and 2022. With these funds... |
| 14.10.2020 | aptaTargets cierra una segunda ronda de €5M, acuden Inveready y el CDTI | 14/10/2020 Nota de prensa APTATARGETS CIERRA UNA SEGUNDA RONDA DE FINANCIACIÓN DE 5 MILLONES DE EUROS. Inveready y el CDTI apoyarán a la empresa de biotecnología para completar un ensayo clínico en pacientes de ictus Madrid, 14 de octub... |
| 18.05.2017 | AptaTargets cierra una ronda de €2,7 millones, acuden Caixa Capital Risc e Inveready | 18/05/2017 Nota de prensa APTATARGETS CIERRA UNA RONDA DE €2,7 MILLONES, ACUDEN CAIXA CAPITAL RISC E INVEREADY. Las entidades de capital riesgo (venture capital) Caixa Capital Risc, e Inveready han invertido €2,7 millones en la compañía ... |
| 17.05.2017 | AptaTargets Raises €2.7m in VC Funding | AptaTargets, a Madrid, Spain-based biopharmaceutical company, raised €2.7m in funding. Backers included Caixa Capital Risc and Inveready. The company intends to use the funds to complete the preclinical phase and move into phase I and II cl... |